17,261 trials
Head and Neck Cancer
Primary: Two-Year Progression Free Survival (PFS) Probability, the Percentage of Patients Estimated to be Alive Without Worsening of Their Disease Two Years After Beginning…
Tourette Syndrome
Primary: Yale Global Tic Severity Scale (Y-GTSS) — 29.5; 31.5 units on a scale
Extensive Stage Small Cell Lung Cancer
Primary: Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST) — 0.697; 0.576 proportion of participants
Breast Cancer
Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 7.4; 3.8; 4.4 months — p=0.003
Lung Cancer · Precancerous Condition
Primary: Change in Average (Follow-up - Baseline) From All Biopsies — -0.23; -0.02 WHO Units
Kidney Diseases
Primary: Biopsy Proven Acute Rejection (BPAR) — 2.3; 9.1; 10.7; 5.8 percentage of participants
Leukemia
Primary: Measure Patient Response to High-dose Cytarabine Followed by Clofarabine in Adult Patients With Relapsed or Refractory AML — 17 participants
Pathological Gambling
Primary: Statistically Significant (p<0.05) Decrease From Baseline in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling — 13.9 YBOCS score
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Complete Response + Partial Response + Stable Disease > 24 Weeks — 35 participants
Bleeding (Oozing) in Hepatic Resection
Primary: Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application — 82.9; 37.1 percentage of participants — p=<0.001
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants
Esophageal Cancer
Primary: Peri-operative Mortality at 30 Days — 0.029 proportion of participants
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Colon Cancer · Precancerous Condition · Rectal Cancer
Primary: Percent Change in Number of Rectal Aberrant Cryptic Foci (ACF) as Measured by Magnification Chromoendoscopy — 8.4; -13.3; -8.8; -8.6 percent change in number of ACF…